Eupraxia Pharmaceuticals Inc. has strengthened its executive leadership team to support its next phase of clinical and commercial development. The clinical-stage biotechnology company appointed Dr. Jeff Millard as Executive Vice President, Technical Operations, and Dr. Alex Therien as Executive Vice President, Research & Development, effective July 13, 2026. These changes come as Eupraxia prepares for the Q4 2026 interim release of its RESOLVE trial in Eosinophilic Esophagitis (EOE) and transitions to a cross-border two-hub organization.

Dr. Millard brings nearly 25 years of leadership experience in technical operations, CMC, and regulatory strategy. He previously held senior leadership positions at Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics. At Eupraxia, he will lead critical functions focused on the transition from development to commercialization, with a specific emphasis on the success of EP104GI.

Dr. Therien, who joined Eupraxia in November 2025, assumes leadership of Research & Development. He brings more than 20 years of biopharmaceutical leadership experience, having held senior roles at Generate Biomedicines, Eikon Therapeutics, and Merck. His appointment is aimed at driving portfolio expansion at the company.

As part of the organizational evolution, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle. This shift reflects the company's focus on supporting growing clinical operations. Key clinical, manufacturing, and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

Amanda Malone has stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026. The company acknowledged her contributions in research and early-stage development during her tenure based in Victoria.

Executive Appointments

Eupraxia's proprietary Diffusphere technology is designed to optimize local, controlled drug delivery. The company's lead product candidate, EP-104GI, is currently in a Phase 1b/2 trial for the treatment of EoE. Additionally, Eupraxia completed a Phase 2b clinical trial of EP-104IAR for pain due to knee osteoarthritis, which met its primary endpoint and three of four secondary endpoints.

Oppenheimer analyst Jay Olson has initiated coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17. The rating reflects a positive outlook on the company's performance potential.

Analyst Details

The coverage initiation was led by Jay Olson, an analyst at Oppenheimer. The Outperform rating suggests the stock is expected to perform better than the market average.

Eupraxia Pharmaceuticals is listed on NASDAQ under the ticker symbol EPRX.